- https://www.secondgenome.com/about
- https://www.secondgenome.com/pipeline
- https://www.secondgenome.com/platform
- https://www.secondgenome.com/news
- https://www.secondgenome.com/culture-careers
- https://www.secondgenome.com/about/our-story
- https://www.secondgenome.com/about/leadership
- https://www.secondgenome.com/about/board
- https://www.secondgenome.com/about/advisors
- https://www.secondgenome.com/about/strategic-partnerships
- https://www.secondgenome.com/pipeline/disease-focus-areas
- https://www.secondgenome.com/platform/data-generation
- https://www.secondgenome.com/platform/data-processing
- https://www.secondgenome.com/platform/nomination-lead-prioritization
- https://www.secondgenome.com/platform/classic-drug-development
- https://www.secondgenome.com/platform/microbiome-technologies
- https://www.secondgenome.com/platform/data-analysis-tools
- https://www.secondgenome.com/news/publications
- https://www.secondgenome.com/news/events
- https://www.secondgenome.com/news/posters
- https://www.secondgenome.com/culture-careers/careers
- https://www.secondgenome.com/culture-careers/our-values
- https://www.secondgenome.com/culture-careers/employee-experience
- https://www.secondgenome.com/culture-careers/team-spotlights
- https://www.secondgenome.com/news/fortune-and-great-place-to-work-name-second-genome-a-top-10-best-workplace-in-biopharma
- https://www.secondgenome.com/news/second-genome-expands-development-of-cns-platform-to-validate-microbial-products-as-therapeutics-for-autism-spectrum-disorder
- https://www.secondgenome.com/news/second-genome-doses-first-patient-in-phase-2-clinical-study-of-sgm-1019-for-the-treatment-of-nonalcoholic-steatohepatitis-nash
- https://www.secondgenome.com/news/second-genome-appoints-karim-dabbagh-phd-chief-executive-officer
- https://www.secondgenome.com/news/second-genome-certified-great-place-work
- https://www.linkedin.com/company/1857297/
- https://www.facebook.com/secondgenome
- https://twitter.com/secondgenome
No hay comentarios:
Publicar un comentario